Previous studies have underscored its role in overcoming drug resistance; for example, Yin et al. demonstrated that chidamide mitigated resistance to imatinib or nilotinib in chronic myeloid leukemia with the T315I mutation through modulation of the Akt-autophagy pathway [27]. This evidence concerns the gene AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive.